p53 expression is of independent predictive value in lymph node-negative breast carcinoma.

[1]  L. Norton,et al.  p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Elledge,et al.  p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. , 1994, Cancer research.

[3]  J. Benhattar,et al.  p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[4]  H. Battifora.  p53 immunohistochemistry: a word of caution. , 1994, Human pathology.

[5]  K. Friedrichs,et al.  Overexpression of p53 and prognosis in breast cancer , 1993, Cancer.

[6]  F. Crivelli,et al.  Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. , 1993, American journal of clinical pathology.

[7]  S. Syrjänen,et al.  p53 protein expression in breast cancer as related to histopathological characteristics and prognosis , 1993, International journal of cancer.

[8]  U. Veronesi,et al.  p53 as an independent prognostic marker in lymph node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.

[9]  D. Barnes,et al.  Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? , 1993, Human pathology.

[10]  I. Ellis,et al.  p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. , 1993, Human pathology.

[11]  M. Schmitt,et al.  Accumulation of p53 Protein as an Indicator for p53 Gene Mutation in Breast Cancer: Occurrence of False‐Positives and False‐Negatives , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[12]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[13]  P. Lipponen.  Over‐expression of p53 nuclear oncoprotein in transitional‐cell bladder cancer and its prognostic value , 1993, International journal of cancer.

[14]  G. Serio,et al.  p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. , 1992, American journal of clinical pathology.

[15]  B. Angus,et al.  Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study , 1992, The Journal of pathology.

[16]  T. Visakorpi,et al.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.

[17]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[18]  M. Barbareschi,et al.  Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms , 1992, The Journal of pathology.

[19]  D. Wynford‐Thomas.  Oncogenes and anti‐oncogenes; the molecular basis of tumour behaviour , 1991, The Journal of pathology.

[20]  M. Willingham,et al.  Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  E. Campo,et al.  Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. , 1991, Cancer research.

[22]  J. Herndon,et al.  Relation between p53 overexpression and established prognostic factors in breast cancer. , 1991, Surgery.

[23]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[24]  D. Neal,et al.  Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. , 1991, British Journal of Cancer.

[25]  B. Angus,et al.  p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study , 1991, Journal of Pathology.

[26]  C. Purdie,et al.  p53 expression in colorectal tumors. , 1991, The American journal of pathology.

[27]  E. Appella,et al.  Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  W. Lee,et al.  Tumor suppressor genes: new prospects for cancer research. , 1991, Journal of the National Cancer Institute.

[29]  J. Bartek,et al.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro , 1990, International journal of cancer.

[30]  S. Fields,et al.  Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.

[31]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[32]  T. Maimets,et al.  p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. , 1990, Oncogene.

[33]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[34]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[35]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[36]  F. Rilke,et al.  P53 expression in breast cancer , 1988, International journal of cancer.

[37]  N. Keiding,et al.  Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. , 1987, Cancer research.

[38]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[39]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.